- Home
- PHUN vs KLRS Comparison
PHUN vs KLRS Comparison
Compare PHUN & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- KLRS
- Stock Information
- Founded
- PHUN 2009
- KLRS 2019
- Country
- PHUN United States
- KLRS United States
- Employees
- PHUN N/A
- KLRS N/A
- Industry
- PHUN EDP Services
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PHUN Technology
- KLRS Health Care
- Exchange
- PHUN Nasdaq
- KLRS Nasdaq
- Market Cap
- PHUN 55.9M
- KLRS 46.0M
- IPO Year
- PHUN N/A
- KLRS N/A
- Fundamental
- Price
- PHUN $2.36
- KLRS $4.77
- Analyst Decision
- PHUN Buy
- KLRS Strong Buy
- Analyst Count
- PHUN 2
- KLRS 3
- Target Price
- PHUN $7.75
- KLRS $21.50
- AVG Volume (30 Days)
- PHUN 192.6K
- KLRS 96.6K
- Earning Date
- PHUN 11-06-2025
- KLRS 11-13-2025
- Dividend Yield
- PHUN N/A
- KLRS N/A
- EPS Growth
- PHUN N/A
- KLRS N/A
- EPS
- PHUN N/A
- KLRS N/A
- Revenue
- PHUN $2,357,000.00
- KLRS N/A
- Revenue This Year
- PHUN N/A
- KLRS N/A
- Revenue Next Year
- PHUN $72.40
- KLRS N/A
- P/E Ratio
- PHUN N/A
- KLRS N/A
- Revenue Growth
- PHUN N/A
- KLRS N/A
- 52 Week Low
- PHUN $2.21
- KLRS $2.14
- 52 Week High
- PHUN $6.29
- KLRS $17.24
- Technical
- Relative Strength Index (RSI)
- PHUN 38.33
- KLRS 51.06
- Support Level
- PHUN $2.21
- KLRS $4.50
- Resistance Level
- PHUN $2.40
- KLRS $5.10
- Average True Range (ATR)
- PHUN 0.11
- KLRS 0.43
- MACD
- PHUN -0.03
- KLRS -0.01
- Stochastic Oscillator
- PHUN 19.05
- KLRS 57.14
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.